Christina Poh described the real-world data from eight CUBIC centers as highly encouraging, interpreting response rates that match or exceed those seen in pivotal trials in a heavily pretreated and older patient population as confirmation that bispecific antibodies are a broadly active and impressive class of treatment that already plays an important role in relapsed or refractory follicular lymphoma.
Rising drug prices strain value-based oncology; experts weigh contracting, formulary choices, and home health dosing to cut costs and expand equitable access.
Clinicians brace for rapid multiple myeloma approvals, weighing patient-centered maintenance tradeoffs, long-term toxicity, costs, and emerging MRD-guided stopping decisions.
Christina Poh described the early phase efficacy data for golcadomide as highly impressive, noting that the high overall response rates and durability of responses a very promising signal that she expects will translate into a meaningful role for this first-in-class oral CELMoD agent in the relapsed or refractory follicular lymphoma treatment landscape in the near future.
Christina Poh discussed how the trial data reporting a PFS benefit of 88.9% versus 66.7% at 5 years and an OS advantage for IFRT plus rituximab maintenance in stage III follicular lymphoma does not entirely overturn the conventional view of radiation as a primarily early-stage tool, but does meaningfully challenge the assumption that radiotherapy has no role in advanced-stage disease while noting that additional studies are needed to confirm these findings and to evaluate radiation's role in combination with systemic therapies beyond rituximab.
How cost, access and pharmacy logistics shape second-line relapse therapy—CAR T vs bispecifics—plus strategies to win coverage and cut care costs.
Christina Poh examined the highly individualized nature of the rituximab versus obinutuzumab decision in follicular lymphoma, framing it as a patient-specific assessment that must weigh efficacy advantages against a meaningfully higher tolerability burden that may not be appropriate for all patients.
Christina Poh reviewed the inMIND safety data, noting that the addition of tafasitamab to the lenalidomide and rituximab backbone produced a manageable safety profile that was generally consistent with the R² backbone alone with no major unexpected safety signals observed and overall good patient tolerability throughout the trial.
Learn how myeloma experts sequence BCMA vs GPRC5D bispecifics, manage CRS with prophylactic tocilizumab, and plan for CELMoDs.
New myeloma data show teclistamab+daratumumab slashes relapse risk (HR 0.17), reshaping second-line choices beyond CAR T.
Christina Poh confirmed that the disconnect between provider and patient experiences of shared decision-making resonates strongly with what she observes in clinical practice, noting that while care teams tend to focus on efficacy and side effect profiles, the questions patients ask most frequently are logistical in nature, underscoring that closing this gap requires not only better communication, but also more robust patient navigation support, improved coordination between academic and community settings, and clinical trial designs that better reflect the real-world follicular lymphoma patient population.
Christina Poh discussed how she counsels patients on follicular lymphoma as a chronic, relapsing-remitting disease that is highly treatable, with many patients living for years or even decades with good quality of life, while being transparent that current standard-of-care treatments are unlikely to be curative, framing this honest, forward-looking conversation as the foundation for a long-term therapeutic partnership built on realistic expectations and shared planning.
Learn how daratumumab exposure vs refractoriness guides second-line myeloma therapy, and what MajesTEC trials suggest for BCMA bispecifics.
Explore how experts personalize second-line myeloma care at first relapse, weighing CAR T, bispecifics, and evolving sequencing amid rapid approvals.
In this episode, 'Streamlining Prior Authorization: Strategies for Securing Timely Access to New RRFL Regimens,' Ryan Haumschild, PharmD, MS, MBA, CPEL explores the following question:
This episode, titled 'NCCN Guidelines in Focus: Key Updates for Follicular Lymphoma and Their Impact on Formulary Decisions,' features Ryan Haumschild, PharmD, MS, MBA, CPEL discussing the following critical questions:
Experts weigh meaningful innovation in frontline myeloma therapy against incremental gains, spotlighting patient out-of-pocket costs, financial counseling, and payer-driven formulary decisions.
Experts discuss how MRD testing in myeloma increasingly guides frontline care, yet unanswered questions still limit using MRD as the sole benchmark.
In 'From Promise to Practice: Overcoming Access and Administration Challenges for Bispecifics in RRFL,' Ryan Haumschild, PharmD, MS, MBA, CPEL delves into the following critical question:
In this episode, 'Epcoritamab in RRFL: Efficacy Data, Administration Considerations, and the Pharmacist's Operational Role,' Ryan Haumschild, PharmD, MS, MBA, CPEL explores the following questions:
BCMA ADC belantamab added to DRd shows striking MRD negativity in early myeloma trials, but eye toxicity and access shape frontline use.
Cepheus data shows durable 6‑year control with DVRd, prompting new counseling and tailored dosing for frail, transplant‑ineligible myeloma patients.
This episode, titled 'What It Takes to Make the Pathway: Clinical and Operational Criteria for Adding New Combinations in RRFL,' features Ryan Haumschild, PharmD, MS, MBA, CPEL discussing the following critical question:
In 'From Data to Practice: Interpreting inMIND Trial Results and the Role of Tafasitamab in RRFL,' Ryan Haumschild, PharmD, MS, MBA, CPEL delves into the following critical questions
Experts debate quadruplet myeloma therapy, MRD-guided de-escalation, and risk-adapted intensification—plus how payers may respond.
Experts weigh quadruplet vs triplet myeloma therapy, tailoring to frailty and clots, and push early CAR-T/BCMA options for high-risk patients.
The panelists examined the significant progress made in frontline multiple myeloma treatment while emphasizing that true satisfaction will only come when more patients achieve a durable cure and can transition off maintenance therapy entirely, identifying MRD-guided treatment discontinuation as one of the most promising pathways toward that goal.
Experts unpack new myeloma regimens—quadruplet induction, dual maintenance, earlier smoldering therapy—plus real-world access and cost hurdles.
In this episode, 'Operationalizing RRFL Care: Sequencing Therapies, Managing REMS, and the Role of R² in Practice,' the pharmacist Ryan Haumschild, PharmD, MS, MBA, CPEL explores the following questions: 1. From a pharmacy operations standpoint, how do you characterize the current treatment landscape for relapsed or refractory follicular lymphoma (RRFL), and how has the growing number of available agents affected formulary management and operational planning at your institution? 2. Lenalidomide plus rituximab has been a commonly used combination in RRFL. How have you positioned this regimen in your own practice, and what have been its strengths and limitations in your experience?
